- Home
- ELVN vs VRNS Comparison
ELVN vs VRNS Comparison
Compare ELVN & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | VRNS |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.8B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ELVN | VRNS |
|---|---|---|
| Price | $57.95 | $44.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $43.40 | $42.75 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $270,288,000.00 |
| Revenue This Year | N/A | $18.87 |
| Revenue Next Year | N/A | $17.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 24.35 |
| 52 Week Low | $14.79 | $19.70 |
| 52 Week High | $62.32 | $63.90 |
Technical Indicators
Market Signals| Indicator | ELVN | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 54.75 |
| Support Level | $56.69 | $31.16 |
| Resistance Level | $62.32 | $45.95 |
| Average True Range (ATR) | 1.92 | 1.76 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 57.25 | 68.26 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.